Experience with Linezolid for the Treatment of Rifampin-Susceptible Tuberculosis in San Francisco.

Janice K Louie, Gustavo E Velásquez, Allison Phillips, John D Szumowski

Abstract read

In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Janice K LouieTuberculosis Prevention and Control Program, San Francisco Department of Public Health, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-6568-5213

Gustavo E VelásquezDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.

Allison PhillipsTuberculosis Prevention and Control Program, San Francisco Department of Public Health, San Francisco, California, USA.

John D SzumowskiTuberculosis Prevention and Control Program, San Francisco Department of Public Health, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-0287-9704

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Linezolid is recommended for the treatment of rifampin-resistant tuberculosis (TB), but its role in rifampin-susceptible TB (RS-TB) is less understood. In 45 RS-TB patients treated with linezolid, 8 stopped due to adverse events, most commonly cytopenias. Further research is needed on linezolid efficacy, dosing, and adverse event management in RS-TB.

Indexed as

adverse eventsdrug-susceptiblelinezolidoxazolidinonetuberculosis

Identifiers

PMID41341862

DOI10.1093/ofid/ofaf714

PMCPMC12671394

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.